ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Japan greenlights dexamethasone as second coronavirus treatment

Cheap anti-inflammatory wins fast-track approval after slashing mortality rates in UK hospital trial

A pharmacist holds an ampule of dexamethasone at a hospital in Belgium.   © Reuters

TOKYO -- The Japanese health ministry has authorized the anti-inflammatory drug dexamethasone to treat severe cases of COVID-19 after the inexpensive steroid lowered fatalities by roughly a third in a British trial, marking the second time a candidate has won fast-track approval.

The Ministry of Health, Labor and Welfare revised a handbook Friday to list dexamethasone as an option, following up on Japan's expedited approval in May of the antiviral drug remdesivir. Recipients of either treatment will be covered by insurance.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more